医学
溃疡性结肠炎
优势比
内科学
类固醇
逻辑回归
队列
回顾性队列研究
胃肠病学
外科
疾病
激素
作者
Takahiro Fukuda,Hajime Yamazaki,Yusuke Miyatani,Tsunaki Sawada,Naoki Shibuya,Yuka Fukuo,Hiroki Kiyohara,Hiromu Morikubo,Keiichi Tominaga,Kazuki Kakimoto,Takayuki Imai,Katsuki Yaguchi,Shojiro Yamamoto,Katsuyoshi Ando,Nobuaki Nishimata,Takeo Yoshihara,Katsuyoshi Ando,Toshifumi Hibi,Katsuyoshi Matsuoka
摘要
Summary Background Endoscopic healing (EH) is a therapeutic target in ulcerative colitis (UC). However, even patients who have achieved EH relapse frequently. Aims To investigate the association between recent steroid use and relapse risk in UC patients with EH. Methods This multi‐centre cohort study included 1212 UC patients with confirmed EH (Mayo endoscopic subscore ≤1). We excluded patients with current systemic steroid use or history of advanced therapy. We divided patients into a recent steroid group (last systemic steroid use within 1 year; n = 59) and a non‐recent or steroid‐naïve group ( n = 1153). We followed the patients for 2 years to evaluate relapse, defined as induction of systemic steroids or advanced therapy. We used logistic regression to estimate the odds ratio (OR) of relapse. Results Relapse occurred in 28.8% of the recent steroid group and 5.6% of the non‐recent/steroid‐naïve group (multi‐variable‐adjusted OR 5.53 [95% CI 2.85–10.7]). The risk of relapse decreased with time since the last steroid use: 28.8% for less than 1 year after steroid therapy, 22.9% for 1 year, 16.0% for 2 years and 7.9% beyond 3 years, approaching 4.0% in steroid‐naïve patients. ( p trend <0.001). Conclusions Even for patients with UC who achieved EH, the risk of relapse remains high following recent steroid therapy. Physicians need to consider the duration since last steroid use to stratify the relapse risk in UC patients with EH.
科研通智能强力驱动
Strongly Powered by AbleSci AI